GleamWall
中文EN

UTHR UNITED THERAPEUTICS Corp

Pharmaceutical Preparations · Nasdaq · SEC CIK 1082554 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY1.9%
TTM net income YoY-3.2%
TTM EPS YoY0.4%
Revenue 3-yr CAGR13.1%
Net income 3-yr CAGR11.0%

Margins

Gross margin86.3%
Operating margin41.4%
Net margin38.6%
FCF margin27.2%
EBITDA margin44.5%

Returns

ROE19.1%
ROA17.1%
ROIC (approx.)20.9%
Asset turnover0.44x

Leverage & solvency

Liabilities / assets10.8%
Debt / equity0.00x
Current ratio4.61x
Interest coverage111.02x

Cash quality & payout

Operating cash flow / net income1.16x
Accruals ratio-2.8%
Payout ratio—
Capex / revenue17.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$832.50M$783.30M$781.50M$790.20M$799.50M$798.60M$794.40M$735.90M
Cost of revenue$99.10M$99.50M$133.40M$103.40M$100.90M$87.60M$92.50M$75.90M
Gross profit$733.40M$683.80M$648.10M$686.80M$698.60M$711.00M$701.90M$660.00M
R&D expense$279.20M$146.30M$138.20M$139.50M$127.50M$134.00M$149.00M$133.80M
SG&A expense$146.40M$206.70M$184.10M$190.60M$182.60M$212.50M$170.10M$168.50M
Operating income$307.80M$330.80M$325.80M$356.70M$388.50M$364.50M$382.80M$357.70M
Interest expense$2.90M$2.90M$3.00M$3.10M$3.00M$7.30M$6.10M$7.90M
Pretax income$372.80M$372.70M$318.30M$444.00M$438.00M$408.40M$423.50M$396.50M
Income tax$114.20M$39.70M$43.40M$79.70M$99.30M$98.90M$101.30M$95.20M
Net income$258.60M$333.00M$274.90M$364.30M$338.70M$309.50M$322.20M$301.30M
EBITDA$334.20M$355.00M$348.40M$379.50M$410.40M$385.60M$402.60M$377.40M
EPS (basic)6.067.826.32—7.736.867.18—
EPS (diluted)5.717.275.82—7.166.416.63—
Weighted avg. shares (diluted)45.30M45.80M47.20M—47.30M48.30M48.60M—
Balance sheet
Cash & equivalents$1.19B$1.80B$1.28B$1.56B$1.34B$1.59B$1.90B$1.70B
Short-term investments$879.00M$859.10M$874.00M$1.36B$1.43B$1.46B$1.42B$1.57B
Receivables$348.60M$310.30M$312.00M$350.20M$297.70M$379.30M$322.00M$279.30M
Inventory$201.90M$193.80M$178.30M$183.10M$176.50M$169.20M$165.40M$157.90M
Current assets$2.88B$3.48B$2.87B$3.70B$3.49B$3.83B$3.94B$3.87B
PP&E, net$2.04B$1.93B$1.84B$1.73B$1.56B$1.36B$1.30B$1.22B
Goodwill———$32.30M———$32.30M
Total assets$7.03B$7.22B$6.71B$7.88B$7.35B$7.91B$7.74B$7.36B
Current liabilities$624.30M$607.80M$599.10M$560.60M$546.30M$527.10M$721.50M$738.10M
Total liabilities$758.10M$819.80M$813.10M$783.80M$760.90M$734.40M$936.70M$920.00M
Shareholders' equity$6.28B$6.40B$5.90B$7.10B$6.59B$7.17B$6.81B$6.44B
Shares outstanding42.38M42.68M42.16M43.64M42.90M45.22M45.07M44.83M
Cash flow statement
Operating cash flow$306.50M$313.60M$463.30M$346.20M$562.10M$191.70M$461.20M$341.20M
Capital expenditure$180.70M$108.00M$100.80M$172.90M$210.50M$62.20M$74.90M$86.70M
Free cash flow$125.80M$205.60M$362.50M$173.30M$351.60M$129.50M$386.30M$254.50M
Investing cash flow-$510.60M$87.50M$743.70M-$227.60M$140.90M-$299.90M-$164.70M-$123.20M
Financing cash flow-$410.20M$122.40M-$1.48B$98.40M-$956.00M-$198.60M-$93.80M-$74.70M
Depreciation & amortization$26.40M$24.20M$22.60M$22.80M$21.90M$21.10M$19.80M$19.70M
Stock-based compensation$41.00M$43.40M$33.90M$39.00M$39.10M$37.80M$31.80M$27.00M
Share buybacks$500.00M$0$1.50B$0$1.00B$0$0$0

Free plan shows the latest 8 periods; Pro shows all 70 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.